Betoptic S

See also: Generic Betoptic

Betoptic S is a brand name of betaxolol ophthalmic, approved by the FDA in the following formulation(s):

BETOPTIC S (betaxolol hydrochloride - suspension/drops; ophthalmic)

• 
  Manufacturer: ALCON
  
  Approval date: December 29, 1989
  
  Strength(s): EQ 0.25% BASE ^[RLD]

Has a generic version of Betoptic S been approved?

No. There is currently no therapeutically equivalent version of Betoptic S available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Betoptic S. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Betoptic S.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 8, 2010 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Betoptic-S Drops Consumer Information (Wolters Kluwer)
• Betoptic S Consumer Information (Cerner Multum)
• Betoptic S Advanced Consumer Information (Micromedex)
• Betoptic S eent AHFS DI Monographs (ASHP)
• Betaxolol Drops Consumer Information (Wolters Kluwer)
• Betaxolol ophthalmic Consumer Information (Cerner Multum)
• Betaxolol Ophthalmic Advanced Consumer Information (Micromedex)
• Betaxolol Hydrochloride eent AHFS DI Monographs (ASHP)

Byetta

Byetta is a brand name of exenatide, approved by the FDA in the following formulation(s):

BYETTA (exenatide synthetic - injectable; subcutaneous)

• 
  Manufacturer: AMYLIN
  
  Approval date: April 28, 2005
  
  Strength(s): 300MCG/1.2ML (250MCG/ML) ^[RLD], 600MCG/2.4ML (250MCG/ML) ^[RLD]

Has a generic version of Byetta been approved?

No. There is currently no therapeutically equivalent version of Byetta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Byetta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
  Patent 5,424,286
  Issued: June 13, 1995
  Inventor(s): Eng; John
  This invention encompasses pharmaceutical compositions containing exendin-3 or exendin-4, fragments thereof, or any combination thereof, and methods for the treatment of diabetes mellitus and the prevention of hyperglycemia.
  
  Patent expiration dates:
  
  
  • December 1, 2016
    
    ✓ 
    Patent use: STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
  
  
  
  • December 1, 2016
    
    ✓ 
    Patent use: TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE
  
  



• 
  Methods for regulating gastrointestinal motility
  Patent 6,858,576
  Issued: February 22, 2005
  Inventor(s): Young; Andrew A. & Gedulin; Bronislava & Beeley; Nigel Robert Arnold & Prickett; Kathryn S.
  Assignee(s): Amylin Pharmaceuticals, Inc.
  Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
  
  Patent expiration dates:
  
  
  • January 6, 2017
    
    ✓ 
    Patent use: REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
  
  



• 
  Methods for glucagon suppression
  Patent 6,872,700
  Issued: March 29, 2005
  Inventor(s): Young; Andrew A. & Gedulin; Bronislava
  Assignee(s): Amylin Pharmaceuticals, Inc.
  Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provide. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.
  
  Patent expiration dates:
  
  
  • January 14, 2020
    
    ✓ 
    Patent use: LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4
  
  



• 
  Exendin agonist formulations and methods of administration thereof
  Patent 6,902,744
  Issued: June 7, 2005
  Inventor(s): Kolterman; Orville G. & Young; Andrew A.
  Assignee(s): Amylin Pharmaceuticals, Inc.
  Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
  
  Patent expiration dates:
  
  
  • January 14, 2020
    
    ✓ 
    Drug product
  
  



• 
  Use of exendins for the reduction of food intake
  Patent 6,956,026
  Issued: October 18, 2005
  Inventor(s): Beeley; Nigel Robert Arnold & Bhavsar; Sunil
  Assignee(s): Amylin Pharmaceuticals, Inc.
  Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
  
  Patent expiration dates:
  
  
  • January 7, 2018
    
    ✓ 
    Patent use: REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
  
  



• 
  Pharmaceutical compositions containing exendins
  Patent 7,297,761
  Issued: November 20, 2007
  Inventor(s): Beeley; Nigel Robert Arnold & Prickett; Kathryn S. & Bhavsar; Sunil & Young; Andrew & Gedulin; Bronislava
  Assignee(s): Amylin Pharmaceuticals, Inc.
  Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
  
  Patent expiration dates:
  
  
  • October 15, 2017
    
    ✓ 
    Drug product
  
  



• 
  Exendin pharmaceutical compositions
  Patent 7,521,423
  Issued: April 21, 2009
  Inventor(s): Young; Andrew A. & Gedulin; Bronislava
  Assignee(s): Amylin Pharmaceuticals, Inc.
  Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
  
  Patent expiration dates:
  
  
  • October 15, 2017
    
    ✓ 
    Drug product
  
  



• 
  Exendins and exendin agonists for weight reduction and obesity
  Patent 7,741,269
  Issued: June 22, 2010
  Inventor(s): Young; Andrew A. & Bhavsar; Sunil & Gedulin; Bronislava
  Assignee(s): Amylin Pharmaceuticals, Inc.
  Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
  
  Patent expiration dates:
  
  
  • January 7, 2018
    
    ✓ 
    Patent use: USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT
  
  

See also...

• Byetta Consumer Information (Drugs.com)
• Byetta Consumer Information (Wolters Kluwer)
• Byetta Consumer Information (Cerner Multum)
• Byetta Prefilled Pen Consumer Information (Cerner Multum)
• Byetta Advanced Consumer Information (Micromedex)
• Byetta AHFS DI Monographs (ASHP)
• Exenatide Consumer Information (Wolters Kluwer)
• Exenatide Consumer Information (Cerner Multum)
• Exenatide Subcutaneous Advanced Consumer Information (Micromedex)
• Exenatide AHFS DI Monographs (ASHP)

Bystolic

Bystolic is a brand name of nebivolol, approved by the FDA in the following formulation(s):

BYSTOLIC (nebivolol hydrochloride - tablet; oral)

• 
  Manufacturer: FOREST LABS
  
  Approval date: December 17, 2007
  
  Strength(s): EQ 10MG BASE, EQ 2.5MG BASE, EQ 5MG BASE
  


• 
  Manufacturer: FOREST LABS
  
  Approval date: October 8, 2008
  
  Strength(s): EQ 20MG BASE ^[RLD]

Has a generic version of Bystolic been approved?

No. There is currently no therapeutically equivalent version of Bystolic available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bystolic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compositions containing micronized nebivolol
  Patent 5,759,580
  Issued: June 2, 1998
  Inventor(s): Jans; Eugeen Marie Jozef & Smans; Guido Franciscus & Gilis; Paul Marie Victor
  Assignee(s): Janssen Pharmaceutica, N.V.
  The present invention relates to pharmaceutical compositions containing as active ingredient micronized nebivolol of formula (I) and ways of preparing said compositions. ##STR1##
  
  Patent expiration dates:
  
  
  • June 2, 2015
    
    ✓ 
    Drug product
  
  



• 
  Method of lowering the blood pressure
  Patent 6,545,040
  Issued: April 8, 2003
  Inventor(s): Raymond Mathieu; Xhonneux & Guy Rosalia Eugène; Van Lommen
  Assignee(s): Janssen Pharmaceutica N.V.
  A method of potentiating the effects of blood pressure reducing agents in warm-blooded animals, said method comprising administering to said warm-blooded animals of an effective amount of a blood pressure reducing agent and a 2,2′-iminobisethanol derivative.
  
  Patent expiration dates:
  
  
  • December 17, 2021
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 17, 2012 - NEW CHEMICAL ENTITY
  
  

See also...

• Bystolic Consumer Information (Drugs.com)
• Bystolic Consumer Information (Wolters Kluwer)
• Bystolic Consumer Information (Cerner Multum)
• Bystolic Advanced Consumer Information (Micromedex)
• Bystolic AHFS DI Monographs (ASHP)
• Nebivolol Consumer Information (Wolters Kluwer)
• Nebivolol Consumer Information (Cerner Multum)
• Nebivolol Advanced Consumer Information (Micromedex)
• Nebivolol Hydrochloride AHFS DI Monographs (ASHP)

Brovana

Brovana is a brand name of arformoterol, approved by the FDA in the following formulation(s):

BROVANA (arformoterol tartrate - solution; inhalation)

• 
  Manufacturer: SUNOVION
  
  Approval date: October 6, 2006
  
  Strength(s): EQ 0.015MG BASE/2ML ^[RLD]

Has a generic version of Brovana been approved?

No. There is currently no therapeutically equivalent version of Brovana available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brovana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
  Patent 5,795,564
  Issued: August 18, 1998
  Inventor(s): Aberg; Gunnar & Morley; John
  Assignee(s): Sepracor, Inc.
  A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased bronchial distribution when administered by inhalation.
  
  Patent expiration dates:
  
  
  • April 3, 2012
    
    ✓ 
    Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
  
  



• 
  Formoterol process
  Patent 6,040,344
  Issued: March 21, 2000
  Inventor(s): Gao; Yun & Hett; Robert & Fang; Kevin Q. & Wald; Stephen A. & Redmon; Martin P. & Senanayake; Chris Hugh
  Assignee(s): Sepracor Inc.
  A method is disclosed for the preparation of optically pure isomers of formoterol by the reaction of an optically pure 4-benzyloxy-3-formamidostyrene oxide with an optically pure 4-methoxy-.alpha.-methyl-N-(phenylmethyl)benzeneethanamine followed by debenzylation. Useful intermediates in the process are also disclosed, as are the novel L-tartrate salt of R,R-formoterol and pharmaceutical compositions thereof.
  
  Patent expiration dates:
  
  
  • November 12, 2016
    
    ✓ 
    Drug substance
  
  



• 
  Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
  Patent 6,068,833
  Issued: May 30, 2000
  Inventor(s): Aberg; Gunnar & Morley; John
  Assignee(s): Sepracor Inc.
  A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.
  
  Patent expiration dates:
  
  
  • April 3, 2012
    
    ✓ 
    Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
  
  



• 
  Formoterol tartrate process and polymorph
  Patent 6,472,563
  Issued: October 29, 2002
  Inventor(s): Gerald J.; Tanoury & Chris H.; Senanayake & Donald W; Kessler
  Assignee(s): Sepracor Inc.
  A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
  
  Patent expiration dates:
  
  
  • November 9, 2021
    
    ✓ 
    Drug substance
  
  



• 
  Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
  Patent 6,589,508
  Issued: July 8, 2003
  Inventor(s): Gunnar; Aberg & John; Morley
  Assignee(s): Sepracor Inc.
  A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.
  
  Patent expiration dates:
  
  
  • April 3, 2012
    
    ✓ 
    Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
  
  



• 
  Formoterol tartrate polymorph
  Patent 6,720,453
  Issued: April 13, 2004
  Inventor(s): Gerald J.; Tanoury & Chris H.; Senanayake & Donald W; Kessler
  Assignee(s): Sepracor Inc.
  A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
  
  Patent expiration dates:
  
  
  • November 9, 2021
    
    ✓ 
    Drug substance
  
  



• 
  Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
  Patent 6,866,839
  Issued: March 15, 2005
  Inventor(s): Aberg; Gunnar & Morley; John
  Assignee(s): Sepracor Inc.
  A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.
  
  Patent expiration dates:
  
  
  • April 3, 2012
    
    ✓ 
    Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
  
  



• 
  Formoterol tartrate polymorph
  Patent 7,145,036
  Issued: December 5, 2006
  Inventor(s): Tanoury; Gerald J. & Senanayake; Chris H. & Kessler; Donald W.
  Assignee(s): Sepracor Inc.
  A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
  
  Patent expiration dates:
  
  
  • November 9, 2021
    
    ✓ 
    Drug substance
  
  



• 
  Formoterol tartrate process and polymorph
  Patent 8,110,706
  Issued: February 7, 2012
  Inventor(s): Tanoury; Gerald J. & Senanayake; Chris H. & Kessler; Donald W.
  Assignee(s): Sunovion Pharmaceuticals Inc.
  A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
  
  Patent expiration dates:
  
  
  • November 9, 2021
    
    ✓ 
    Drug product
  
  

See also...

• Brovana Consumer Information (Drugs.com)
• Brovana Consumer Information (Wolters Kluwer)
• Brovana Consumer Information (Cerner Multum)
• Brovana Advanced Consumer Information (Micromedex)
• Brovana AHFS DI Monographs (ASHP)
• Arformoterol Consumer Information (Wolters Kluwer)
• Arformoterol inhalation Consumer Information (Cerner Multum)
• Arformoterol Inhalation Advanced Consumer Information (Micromedex)
• Arformoterol Tartrate AHFS DI Monographs (ASHP)

Fragmin

Fragmin is a brand name of dalteparin, approved by the FDA in the following formulation(s):

FRAGMIN (dalteparin sodium - injectable; subcutaneous)

• 
  Manufacturer: EISAI INC
  
  Approval date: December 22, 1994
  
  Strength(s): 2,500IU/0.2ML (12,500IU/ML)
  


• 
  Manufacturer: EISAI INC
  
  Approval date: March 18, 1996
  
  Strength(s): 5,000IU/0.2ML (25,000IU/ML)
  


• 
  Manufacturer: EISAI INC
  
  Approval date: January 30, 1998
  
  Strength(s): 10,000IU/ML (10,000IU/ML)
  


• 
  Manufacturer: EISAI INC
  
  Approval date: April 4, 2002
  
  Strength(s): 7,500IU/0.3ML (25,000IU/ML), 95,000IU/3.8ML (25,000IU/ML) ^[RLD], 95,000IU/9.5ML (10,000IU/ML)
  


• 
  Manufacturer: EISAI INC
  
  Approval date: May 1, 2007
  
  Strength(s): 10,000IU/0.4ML (25,000IU/ML), 12,500IU/0.5ML (25,000IU/ML), 15,000IU/0.6ML (25,000IU/ML), 18,000IU/0.72ML (25,000IU/ML)
  

Has a generic version of Fragmin been approved?

No. There is currently no therapeutically equivalent version of Fragmin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fragmin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Fragmin.

See also...

• Fragmin Consumer Information (Drugs.com)
• Fragmin Consumer Information (Wolters Kluwer)
• Fragmin Consumer Information (Cerner Multum)
• Fragmin Advanced Consumer Information (Micromedex)
• Fragmin AHFS DI Monographs (ASHP)
• Dalteparin Consumer Information (Wolters Kluwer)
• Dalteparin Consumer Information (Cerner Multum)
• Dalteparin Subcutaneous Advanced Consumer Information (Micromedex)
• Dalteparin Sodium AHFS DI Monographs (ASHP)

Fosamax

Fosamax is a brand name of alendronate, approved by the FDA in the following formulation(s):

FOSAMAX (alendronate sodium - solution; oral)

• 
  Manufacturer: MERCK
  
  Approval date: September 17, 2003
  
  Strength(s): EQ 70MG BASE/75ML ^[RLD]

FOSAMAX (alendronate sodium - tablet; oral)

• 
  Manufacturer: MERCK AND CO INC
  
  Approval date: September 29, 1995
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 40MG BASE ^[AB]


• 
  Manufacturer: MERCK AND CO INC
  
  Approval date: April 25, 1997
  
  Strength(s): EQ 5MG BASE ^[AB]


• 
  Manufacturer: MERCK AND CO INC
  
  Approval date: October 20, 2000
  
  Strength(s): EQ 35MG BASE ^[AB], EQ 70MG BASE ^[RLD][AB]

Has a generic version of Fosamax been approved?

A generic version of Fosamax has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Fosamax and have been approved by the FDA:

alendronate sodium tablet; oral

• 
  Manufacturer: APOTEX
  
  Approval date: August 4, 2008
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]


• 
  Manufacturer: AUROBINDO PHARMA
  
  Approval date: August 4, 2008
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 70MG BASE ^[AB]


• 
  Manufacturer: AUSTARPHARMA LLC
  
  Approval date: September 24, 2009
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]


• 
  Manufacturer: CADISTA PHARMS
  
  Approval date: February 18, 2010
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]


• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: August 4, 2008
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: August 4, 2008
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB], EQ 70MG BASE ^[AB]


• 
  Manufacturer: SUN PHARMA GLOBAL
  
  Approval date: September 10, 2008
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: February 6, 2008
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 40MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: August 4, 2008
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 40MG BASE ^[AB], EQ 40MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB], EQ 70MG BASE ^[AB]

Note: No generic formulation of the following product is available.

• alendronate sodium - solution; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fosamax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Dry mix formulation for bisphosphonic acids with lactose
  Patent 5,358,941
  Issued: October 25, 1994
  Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
  Assignee(s): Merck & Co., Inc.
  Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
  
  Patent expiration dates:
  
  
  • December 2, 2012
    
  
  
  
  • June 2, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Oral liquid alendronate formulations
  Patent 5,462,932
  Issued: October 31, 1995
  Inventor(s): Brenner; Gerald S. & Katdare; Ashok V. & Pretzer; Denise & Whiteford; Donna T.
  Assignee(s): Merck & Co., Inc.
  Disclosed is a therapy protocol for treating and for preventing bone loss in patients who have difficulty in swallowing by administering a liquid formulation of alendronate which can be easily swallowed. Also described are pharmaceutical dosage forms of a syrup, aqueous solution, a solution formed from a reconstituted powder, of alendronate, for carrying out the therapeutic method.
  
  Patent expiration dates:
  
  
  • May 17, 2014
    
  
  
  
  • November 17, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Dry mix formulation for bisphosphonic acids
  Patent 5,681,590
  Issued: October 28, 1997
  Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
  Assignee(s): Merck & Co., Inc.
  Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
  
  Patent expiration dates:
  
  
  • December 2, 2012
    
  
  
  
  • June 2, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method for inhibiting bone resorption
  Patent 5,994,329
  Issued: November 30, 1999
  Inventor(s): Daifotis; Anastasia G. & Santora, II; Arthur C. & Yates; A. John
  Assignee(s): Merck & Co., Inc.
  Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
  
  Patent expiration dates:
  
  
  • July 17, 2018
    
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • January 17, 2019
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method for inhibiting bone resorption
  Patent 6,015,801
  Issued: January 18, 2000
  Inventor(s): Daifotis; Anastasia G. & Yates; A. John & Santora, II; Arthur C.
  Assignee(s): Merck & Co., Inc.
  Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for caring out the therapeutic methods disclosed herein.
  
  Patent expiration dates:
  
  
  • July 17, 2018
    
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • January 17, 2019
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Dry mix formulation for bisphosphonic acids
  Patent 6,090,410
  Issued: July 18, 2000
  Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
  Assignee(s): Merck & Co., Inc.
  Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
  
  Patent expiration dates:
  
  
  • December 2, 2012
    
  
  
  
  • June 2, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Dry mix formulation for bisphosphonic acids
  Patent 6,194,004
  Issued: February 27, 2001
  Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
  Assignee(s): Merck & Co., Inc.
  Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
  
  Patent expiration dates:
  
  
  • December 2, 2012
    
  
  
  
  • June 2, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method for inhibiting bone resorption
  Patent 6,225,294
  Issued: May 1, 2001
  Inventor(s): Daifotis; Anastasia G. & Santora, II; Arthur C. & Yates; A. John
  Assignee(s): Merck & Co., Inc.
  Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
  
  Patent expiration dates:
  
  
  • July 17, 2018
    
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • January 17, 2019
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Fosamax Consumer Information (Drugs.com)
• Fosamax Consumer Information (Wolters Kluwer)
• Fosamax Solution Consumer Information (Wolters Kluwer)
• Fosamax Consumer Information (Cerner Multum)
• Fosamax Advanced Consumer Information (Micromedex)
• Fosamax AHFS DI Monographs (ASHP)
• Alendronate Consumer Information (Wolters Kluwer)
• Alendronate Solution Consumer Information (Wolters Kluwer)
• Alendronate Consumer Information (Cerner Multum)
• Alendronate Advanced Consumer Information (Micromedex)
• Alendronate Sodium AHFS DI Monographs (ASHP)

Renova

Renova is a brand name of tretinoin topical, approved by the FDA in the following formulation(s):

RENOVA (tretinoin - cream; topical)

• 
  Manufacturer: VALEANT INTL
  
  Approval date: December 29, 1995
  
  Strength(s): 0.05% ^[RLD][AB2]


• 
  Manufacturer: VALEANT INTL
  
  Approval date: August 31, 2000
  
  Strength(s): 0.02% ^[RLD]

Has a generic version of Renova been approved?

A generic version of Renova has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Renova and have been approved by the FDA:

tretinoin cream; topical

• 
  Manufacturer: SPEAR PHARMS
  
  Approval date: September 15, 2005
  
  Strength(s): 0.05% ^[AB2]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Renova. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Oil-in-water emulsion containing tretinoin
  Patent 6,531,141
  Issued: March 11, 2003
  Inventor(s): John; Marvel
  Assignee(s): Ortho-McNeil Pharmaceutical, Inc.
  The present invention relates to an oil-in-water emulsion containing tretinoin and the use thereof in mitigating skin disorders such as acne, photodamaged skin, wrinkles, mottled hyperpigmentation, tactile roughness, and yellowing of facial skin.
  
  Patent expiration dates:
  
  
  • March 7, 2020
    
  
  

See also...

• Renova Consumer Information (Drugs.com)
• Renova Emollient Cream Consumer Information (Wolters Kluwer)
• Renova Consumer Information (Cerner Multum)
• Renova Topical Advanced Consumer Information (Micromedex)
• Retin A Consumer Information (Drugs.com)
• Tretinoin Cream Consumer Information (Wolters Kluwer)
• Tretinoin Emollient Cream Consumer Information (Wolters Kluwer)
• Tretinoin Gel Consumer Information (Wolters Kluwer)
• Tretinoin Liquid Consumer Information (Wolters Kluwer)
• Tretinoin topical Consumer Information (Cerner Multum)
• Rejuva-A Topical Advanced Consumer Information (Micromedex)
• Retin-A Micro Topical Advanced Consumer Information (Micromedex)
• Vitamin A Acid Topical Advanced Consumer Information (Micromedex)
• Tretinoin Topical Advanced Consumer Information (Micromedex)
• Tretinoin topical AHFS DI Monographs (ASHP)